Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 610 participants.

Also called NCT02681016

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 610 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02681016
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02681016. Randomized; single masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2017-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE
Acronym
PATRIOT
Condition
Ischemic Heart Disease
Condition
Coronary Atherosclerosis
Condition
Coronary Artery Stenosis
Intervention (Device)
DES "Calypso"
Intervention (Device)
DES "Xience Prime"
Intervention (Procedure)
Coronary angioplasty
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation (class: research network)

Record details

Record id
cardio:ct-nct02681016
Content hash
6d89b91c51e94ccec1439bf177b975aae00ca09f53bce5c1d724f479042799bf